Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/12478
Type
ArticleCopyright
Restricted access
Collections
- INCQS - Artigos de Periódicos [393]
- IOC - Artigos de Periódicos [12973]
Metadata
Show full item record
REDUCTION OF CELL VIABILITY INDUCED BY IFN-ALPHA GENERATES IMPAIRED DATA ON ANTIVIRAL ASSAY USING HEP-2C CELLS
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biotecnologia e Fisiologia de Infecções Virais. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Programa de Pós-Graduação em Vigilância Sanitária. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biotecnologia e Fisiologia de Infecções Virais. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Programa de Pós-Graduação em Vigilância Sanitária. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Programa de Pós-Graduação em Vigilância Sanitária. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Departamento de Imunologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biotecnologia e Fisiologia de Infecções Virais. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Programa de Pós-Graduação em Vigilância Sanitária. Rio de Janeiro, RJ, Brasil.
Abstract
Type I interferons (IFNs) exert an array of important biological functions on the innate immune
response and has become a useful tool in the treatment of various diseases. An increasing
demand in the usage of recombinant IFNs, mainly due to the treatment of chronic hepatitis C
infection, augmented the need of quality control for this biopharmaceutical. A traditional
bioassay for IFN potency assessment is the cytopathic effect reduction antiviral assay where a
given cell line is preserved by IFN from a lytic virus activity using the cell viability as a frequent
measure of end point. However, type I IFNs induce other biological effects such as cell-cycle
arrest and apoptosis that can influence directly on viability of many cell lines. Here, we
standardized a cytopathic effect reduction antiviral assay using Hep-2C cell/mengovirus
combination and studied a possible impact of cell viability variations caused by IFN-alpha 2b on
responses generated on the antiviral assay. Using the four-parameter logistic model, we
observed less correlation and less linearity on antiviral assay when responses from IFN-alpha 2b
1000 IU/ml were considered in the analysis. Cell viability tests with MTT revealed a clear cell
growth inhibition of Hep-2C cells under stimulation with IFN-alpha 2b. Flow cytometric
cell-cycle analysis and apoptosis assessment showed an increase of S + G2 phase and higher
levels of apoptotic cells after treatment with IFN-alpha 2b 1000 IU/ml under our standardized
antiviral assay procedure. Considering our studied dose range, we also observed strong STAT1
activation on Hep-2C cells after stimulation with the higher doses of IFN-alpha 2b. Our findings
showed that the reduction of cell viability driven by IFN-alpha can cause a negative impact on
antiviral assays. We assume that the cell death induction and the cell growth inhibition effect of
IFNs should also be considered while employing antiviral assay protocols in a quality control
routine and emphasizes the importance of new approaches for IFN potency determination.
Share